The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38)
The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38)
复制标题
DOI：
10.1016/s0959-8049(98)00357-8
复制
发表时间：
1999-02-01
影响因子：
8.4
通讯作者：
Aaronson, NK
中科院分区：
文献类型：
--
作者：
Sprangers, MAG;te Velde, A;Aaronson, NK
本研究的目的是构建一个结直肠癌特异性生活质量（QL）问卷模块，与欧洲癌症研究和治疗组织（EORTC）QLQ-C30结合使用，并在荷兰测试其信度和效度。模块的建造遵循EORTC模块开发指南。“生活质量问卷-CR 38”包括38个项目，涵盖不同治疗模式的症状及副作用、身体形象、性取向及未来展望。该模块在117名结直肠癌患者中进行了多次测试。时间点为放疗或化疗治疗前、治疗期间和第二次评估后3个月。出于重测信度的目的，在第三次评估后1周，患者的子样本完成了QLQ-CR 38。多特质量表分析证实了功能量表的假设量表结构，但没有症状量表。在一项或两项评估中，9个量表中有7个量表的Cronbach α系数超过0.70标准。所有量表和单个项目的重测信度均在0.78以上。其余两个单项的稳定性较低。在已知组比较的基础上，选择性量表明确区分了不同疾病阶段、初始和治疗中的表现状态以及是否存在造口的患者。此外，选择性量表检测随时间的变化，作为性能状态变化和给药诱导变化的函数。这些结果支持QLQ-CR 38作为评估结直肠癌患者相关特定QL问题的补充问卷的临床有效性。需要进一步努力测试该模块的跨文化有效性。(C)1999爱思唯尔科技有限公司。保留所有权利。
The objectives of the current study were to construct a colorectal cancer-specific quality of life (QL) questionnaire module to be used in conjunction with the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and to test its reliability and validity in The Netherlands. Module construction took place following the EORTC guidelines for module development. The module-the QLQ-CR38-consists of 38 items covering symptoms and side-effects related to different treatment modalities, body image, sexuality and future perspective. This module was tested among 117 colorectal cancer patients on several occasions. The timing was prior to treatment with radiotherapy or chemotherapy, during treatment and 3 months following the second assessment. For purposes of test-retest reliability, a subsample of patients completed the QLQ-CR38 1 week following the third assessment. Multitrait scaling analysis confirmed the hypothesised scale structure of the function scales but not of the symptom scales. Cronbach's alpha coefficients for seven of the nine scales exceeded the 0.70 criterion at one or both assessments. The test-retest reliability for all scales and one single item was 0.78 or higher. The stability of the two remaining single items was lower. On the basis of known-groups comparisons, selective scales distinguished clearly between patients differing in disease stage, initial and on-treatment performance status and the presence of a stoma. Additionally, selective scales detected change over time as a function of change in performance status and treatment-induced change. These results lend support to the clinical validity of the QLQ-CR38 as a supplementary questionnaire for assessing specific QL issues relevant to patients with colorectal cancer. Additional efforts to test the module's cross-cultural validity are needed. (C) 1999 Elsevier Science Ltd. All rights reserved.